



ACCADEMIA NAZIONALE DI MEDICINA

Sezione di Oncologia

[Meet the Professor]

20th Meet The Professor Advanced International Breast Cancer Course (AIBCC)

Padova, October 24-25, 2024

Sezione di Oncologia

[Preliminary Program]

Thursday, October 24th

10.30 Introduction to the Conference
Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION

Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly

11.00 Gene expression tools in early-stage HR+/HER2- breast cancer: questioning the grey areas
Alberto Zambelli

11.20 The immune system and breast cancer: TNBC and beyond
Marleen Kok (backup: Maria Vittoria Dieci)

11.40 DNA NGS-based biomarkers to inform treatment sequence in advanced breast cancer
Mafalda Oliveira

12.00 Tackling the biological diversity in HER2-positive breast cancer: clinical implications
Aleix Prat

12.20 Discussion

12.50 *Lunch*

SESSION II – LOCOREGIONAL Tx AND GENOMICS

Chairpersons: Eleftherios Mamounas, Jacek Jassem

14.00 Surgery of the axilla: is less always more?
Oreste Gentilini

14.20 Navigating RT option according to genetic risk profiles
Philip Poortmans

14.40 Evolving concepts in genetic testing: finding the balance
Angela Toss

15.00 Discussion

SESSION III – EARLY BREAST CANCER: NEOADJUVANT AND POST-NEOADJUVANT THERAPY

Chairpersons: Sibylle Loibl, Aleix Prat

15.30 Modulation of neoadjuvant and post-neoadjuvant treatment in HER2+ (pert, TDM1, neratinib, trials)
Sibylle Loibl

15.50 Modulation of neoadjuvant and post-neoadjuvant treatment in TNBC (IO, PARPi, capecitabine)
Valentina Guarneri

Sezione di Oncologia

- 16.10 Indication to and modalities of neoadjuvant Tx in HR+HER2 - BC
Nadia Harbeck
- 16.30 Discussion
- 17.00 Adjourn
- 17.15 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2024
- 17.30 Lecture of the Awardee
- 18.00 Adjourn

Friday, October 25th

SESSION III – EARLY BREAST CANCER

Chairpersons: Alessandra Gennari, Valentina Guarneri

- 9.00 Enhancing efficacy of hormonal therapy in early breast cancer (bisphosphonates, extended, CDK4/6i, SERDs, PARPi...)
Stephen Johnston
- 9.20 Optimizing systemic treatment for small tumors depending on local treatments
Hope Rugo
- 9.40 The challenge of lobular breast cancer
Christine Desmedt
- 10.00 Discussion
- 10.30 *Coffee break*
- 11.00 **Clinical Multidisciplinary Shooting Session 1 – Early Breast Cancer**
Panelists: Bettina Borisch, Hesham Ahmed Gaballah Elghazaly, Jacek Jassem, Sibylle Loibl, Eleftherios Mamounas, Alberto Marchet, Fedro A. Peccatori, Aleix Prat, Philip Poortmans

12.30 *Lunch*

SESSION IV – METASTATIC BREAST CANCER: CONSOLIDATED AND NEW ALGORITHMS

Chairpersons: Pierfranco Conte, Sandra Swain

- 13.30 HR+ disease
Current algorithm: Claudio Vernieri
Adapting the algorithm in a contemporary scenario: Carmen Criscitiello
- 14.00 HER2+ disease
Current algorithm: Federica Miglietta
Treatment sequences in new emerging populations: Sandra Swain
- 14.30 Triple negative disease
Current algorithm: Gaia Griguolo
Treatment sequences in new emerging populations: TBD

Sezione di Oncologia

15.00 Discussion

15.20 **Lecture**

Evidence-based or evidence-biased medicine? Closing the gap between clinical trials and real world data

Pierfranco Conte

15.40 **Clinical Multidisciplinary Shooting Session 2 – Advanced Breast Cancer**

Panelists: Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly, Stephen Johnston, Hope Rugo, Sandra Swain, Philip Poortmans

17.00 Take home messages and adjourn

Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans

[Aims]

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 20th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

[Addressed to]

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

[Honorary President]

Gabriel N. Hortobagyi
Department of Breast Medical Oncology
The University of Texas - MD Anderson Cancer Center
Houston (USA)

Sezione di Oncologia

[Directors]

Pierfranco Conte
Coordinator Molecular Tumor Board, Rete Oncologica Veneta, Padova (I)
Scientific Director S. Camillo Hospital, IRCCS, Venezia (I)

Valentina Guarneri
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Philip Poortmans
Former president of ESTRO and of ECCO
Department of Radiation Oncology
Iridium Netwerk
University of Antwerp
Wilrijk-Antwerp (B)

Alex Prat
Medical Oncology Department
Hospital Clinic
Barcelona (E)

[Scientific Committee]

Bettina Borisch
Institute of Global Health
University of Geneva

Maria Vittoria Dieci
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Hesham Ahmed Gaballah Elghazaly
Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)

Jacek Jassem
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Sezione di Oncologia

Sibylle Loibl
German Breast Group
University of Frankfurt (D)

Eleftherios Mamounas
Comprehensive Breast Program
MD Anderson Cancer Center Orlando
Orlando (F)

Fedro Alessandro Peccatori
Department of Medical Oncology
European Institute of Oncology (IEO)
Milano (I)

Sandra Swain M.
Research Development
Georgetown University Medical Center
Washington (USA)

[Speakers & Chairpersons]

Carmen Criscitiello
Development Division of New Drugs for Innovative Therapies
Istituto Europeo di Oncologia (IEO)
Milano (I)

Christine Desmedt
Laboratory for Translational Breast Cancer Research
Department of Oncology
Leuven (B)

Alessandra Gennari
Division of Oncology
Ospedale Maggiore della Carità
UPO – University of Piemonte Orientale
Novara (I)

Oreste Davide Gentilini
Breast Unit
IRCCS S. Raffaele Hospital
Milano (I)

Gaia Griguolo
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Nadia Harbeck
Management, Breast Center and oncological day clinic
Frauenklinik der Universität München
Munich (G)

Sezione di Oncologia

Marleen Kok
Breast cancer immunotherapy
Netherlands Cancer Institute
Amsterdam (NL)

Alberto Marchet
Breast Surgery Unit 1
Istituto Oncologico Veneto IRCCS
University of Padova (I)

Federica Miglietta
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Mafalda Oliveira
Medical Department of the Vall d'Hebron University
Hospital and Vall d'Hebron Institute of Oncology (VHIO)
Barcelona (E)

Hope Rugo
Breast Oncology Clinical Trials Program
UCSF Carol Franc Buck Breast Care Center
San Francisco (USA)

Angela Toss
Oncology Unit
AOU
Modena (I)

Claudio Vernieri
Institute of Molecular Oncology Oncology and Hemato-Oncology Department
IRCCS Istituto Nazionale dei Tumori
Milano (I)

Alberto Zambelli
Oncology Unit
IRCCS Humanitas
Rozzano – Milano (I)

[Meeting Venue]

Auditorium
Centro Culturale San Gaetano Altinate
Via Altinate, 71
Padova